rs112846763 - PTP4A1P4 - NBPF22P

Magnitude 2.2 · 1 study on file

Reported associations

• Refining antipsychotic treatment strategies in schizophrenia: discovery of genetic biomarkers for enhanced drug response prediction. - Molecular psychiatry (2025) · Chen L, Huai C, Song C, Wu S, Xu Y, Yi Z, Tang J, Fan L, Wu X, Ge Z, Liu C, Jiang D, Weng S, Wang G, Zhang X, Zhao X, Shen L, Zhang N, Wu H, Wang Y, Guo Z, Zhang S, Jiang B, Zhou W, Ma J, Li M, Chu Y, Zhou C, Lv Q, Xu Q, Zhu W, Zhang Y, Lian W, Liu S, Li X, Gao S, Liu A, He L, Yang Z, Dai B, Ye J, Lin R, Lu Y, Yan Q, Hu Y, Xing Q, Huang H, Qin S · PubMed 39562719

  Schizophrenia (SCZ) is a severe mental disorder affecting around 1% of individuals worldwide. The variability in response to antipsychotic drugs (APDs) among SCZ patients presents a significant challenge for clinicians in determining the most effective medication. In this study, we investigated the biological markers and established a predictive model for APD response based on a large-scale genome-wide association study using 3269 Chinese schizophrenia patients. Each participant underwent an 8-week treatment regimen with one of five mono-APDs: olanzapine, risperidone, aripiprazole, quetiapine, or amisulpride. By dividing the response into ordinal groups of "high", "medium", and "low", we mitigated the bias of unclear treatment outcome and identified three novel significantly associated gen

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.